Sokal's63 and Euro64 formulation for the definition of the risk profile at diagnosis. Sokal's formulation was developed from conventionally treated cases (single-agent chemotherapy).The Euro formulation was developed from αIFN treated cases. Low risk patients have a relative risk (RR) < 0.8 with Sokal's and ≤ 780 with Euro. Intermediate risk patients have a RR between 0.8 and 1.2 with Sokal's and between 781 and 1479 with Euro. High risk patients have a RR > 1.2 with Sokal's and ≥ 1480 with Euro.
| . | SOKAL . | EURO . |
|---|---|---|
| (1) Maximum distance from costal margin; (2) Percent in peripheral blood | ||
| Age, years | 0.0116 (age - 43.4) | 0.6666 when age ≥ 50 |
| Spleen (1), cm | 0.0345 (spleen - 7.51) | 0.042 x spleen |
| Platelet, x 109/L | 0.188 [( \(\frac{Platelet}{700}\) )2 - 0.563 ] | 1.0956 when ≥ 1500 |
| Myeloblasts (2), % | 0.0887 (myeloblasts - 2.10) | 0.0584 x myeloblasts |
| Eosinophils (2), % | — | 0.0413 x eosinophils |
| Basophils (2), % | — | 0.2039 when basophils ≥ 3% |
| Relative risk (RR) | Exponential of the total | Total x 1000 |
| . | SOKAL . | EURO . |
|---|---|---|
| (1) Maximum distance from costal margin; (2) Percent in peripheral blood | ||
| Age, years | 0.0116 (age - 43.4) | 0.6666 when age ≥ 50 |
| Spleen (1), cm | 0.0345 (spleen - 7.51) | 0.042 x spleen |
| Platelet, x 109/L | 0.188 [( \(\frac{Platelet}{700}\) )2 - 0.563 ] | 1.0956 when ≥ 1500 |
| Myeloblasts (2), % | 0.0887 (myeloblasts - 2.10) | 0.0584 x myeloblasts |
| Eosinophils (2), % | — | 0.0413 x eosinophils |
| Basophils (2), % | — | 0.2039 when basophils ≥ 3% |
| Relative risk (RR) | Exponential of the total | Total x 1000 |